Baseline biomarkers correlated with outcome in advanced melanoma treated with pembrolizumab monotherapy.
Gil Awada(Universitair Ziekenhuis Brussel), Bart Neyns(Molecular Oncology (United States)), Marleen Keyaerts(Vrije Universiteit Brussel), Julia Katharina Schwarze(Universitair Ziekenhuis Brussel), Mark Kockx(HistoGeneX (Belgium)), Odrade Gondry(Vrije Universiteit Brussel), Teofila Seremet(Vrije Universiteit Brussel), Kara M. Gorman(Nanostring Technologies (United States)), Sarah Warren(Nanostring Technologies (United States)), Hendrik Everaert(Universitair Ziekenhuis Brussel), SuFey Ong(Nanostring Technologies (United States)), Yanina Jansen(Universitair Ziekenhuis Brussel)
Cited by 3
Related Papers
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k
Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy
|Cell Reports|2019|297